Clinical trials located in


Bochum city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Bochum, nestled in the heart of the Ruhr Valley in Germany, is a city rich in history and culture. Once a hub for coal mining and steel production, it has transformed into a vibrant center for education and the arts. Home to the Ruhr University, one of Germany’s largest universities, Bochum fosters a lively student population. The city also boasts the Starlight Express Theater, hosting the world’s longest-running musical. Additionally, the German Mining Museum offers a deep dive into Bochum’s industrial past, making the city a fascinating blend of tradition and modernity.

  • CT-EU-00118687

    Long-term safety and efficacy study of PTC518 for Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the long-term safety and effectiveness of the drug PTC518. Participants, who have previously completed related study phases, will continue taking PTC518 in doses of 5, 10, or 20 milligrams. The study aims to monitor the safety of long-term use and assess how the drug impacts biological markers and symptoms of the disease over a period of 30 months. This is an extension study where all participants will receive the active drug, ensuring continuous monitoring and evaluation of its effects.

    • PTC518
  • Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Study of the combination of semaglutide and empagliflozin in patients with diabetes and non-alcoholic steatohepatitis

    This study is for people with type 2 diabetes who have a liver condition called non-alcoholic steatohepatitis (NASH). Researchers are testing new drug combinations to see if they can treat NASH in diabetic patients. They’re looking at a combo of semaglutide and empagliflozin—medicines that help control blood sugar—and comparing it to empagliflozin alone and a placebo. The main goal is to see if these treatments can improve liver health without harmful side effects. This study is significant because right now, there are no specific drugs approved to treat NASH in those with diabetes​.

    • Empagliflozin
    • Semaglutide
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    • Pemetrexed
    • Nab-paclitaxel
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Domvanalimab
    • Zimberelimab
  • A clinical trial evaluating Tominersen in the treatment of early stages of Huntington’s disease

    This clinical trial is focused on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease, a genetic disorder characterized by the progressive loss of nerve cells in the brain.

    The aim of this study is to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses of this drug or a placebo directly into the spinal cord to reach the areas of the brain most affected by the disease. Participants’ health will be closely monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional well-being. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study provides an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    • Placebo
    • Tominersen
  • R-Pola-Glo therapy for aggressive B-cell lymphoma

    This clinical study tests a new treatment combination called R-Pola-Glo for elderly or medically unfit patients with untreated aggressive B-cell lymphoma. It involves the anti-CD20 antibody rituximab with polatuzumab vedotin and glofitamab, aiming to develop a less intense chemotherapy option. The trial, enrolling 80 participants, will assess the effectiveness and safety of this therapy, which could be crucial for those ineligible for standard treatment due to age or health.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Testing new medication for safety and effect on Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the safety and effectiveness of the drug PTC518. Participants will be randomly assigned to different groups based on their disease stage and will receive either PTC518 in varying doses (5 mg, 10 mg, or 20 mg) or a placebo. The study’s main aim is to observe the drug’s safety and its effects on disease-related proteins and brain changes over 12 months.

    • PTC518- new potential medication for Huntington’s disease
  • Study on the impact of tavapadon on Parkinson’s disease

    This trial is designed to assess a potential treatment for early Parkinson’s disease known as tavapadon. The study spans 27 weeks, during which participants will receive either the actual drug or a placebo (substances without pharmacological effect) in a randomized manner, with neither the individuals nor the researchers knowing who receives which. Parkinson’s disease symptoms will be monitored using a 0-4 scale, where 0 indicates normal and 4 reflects severe impairment across various aspects of daily living and movement. Both the doctor and the participant will assess and score the symptoms and improvements.

    The trial will also include an evaluation of the participant’s personal assessment of change since the start of treatment. Respondents will indicate how much their condition has changed, ranging from very much improved to very much worse. Researchers will additionally examine situations where the participant may feel sleepy, such as reading or sitting in a car for an extended period without a break, scoring between 0 and 3 based on the likelihood of dozing off. The study will monitor potential impulse control disorders, and any side effects or health issues attributable to the treatment.

    • Tavapadon
  • Testing new treatments for hidradenitis suppurativa

    A thorough study is being conducted to evaluate the safety and effectiveness of various investigational treatments for individuals with moderate to severe Hidradenitis Suppurativa (HS), a long-term skin condition characterized by small, painful lumps under the skin. The treatments being tested include CFZ533, LYS006, MAS825, LOU064, and VAY736. Participants in the study will receive one of these potential treatments, aiming to discover whether these novel therapies can significantly reduce the severity of symptoms, improve skin appearance, and enhance the overall quality of life for those affected by this challenging and often painful condition. Throughout the study, participants will undergo regular health checks, including skin assessments and evaluations of any side effects, to ensure their safety and the effectiveness of the treatments.

    • iscalimab/CFZ533
    • LYS006- new potential medication for hidradenitis suppurativa
    • MAS825- new potential medication for inflammatory diseases
    • Remibrutinib/LOU064
    • Ianalumab/VAY736
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Exploring safe treatment options for Multiple Sclerosis

    This study is investigating the effects of Ofatumumab and Siponimod in comparison to a medication called Fingolimod in young patients with Multiple Sclerosis. The study comprises two parts: the Core Part, which spans two years, and the Extension Part, which can last up to five years. In the Core Part, participants are assigned one of the three medications to compare their respective effects. Qualified participants from the Core Part have the option to continue their treatment in the Extension Part. Progress is monitored by assessing the number of disease exacerbations per year, observing changes in scans that detect alterations related to the disease, and conducting blood tests. These blood tests are instrumental in measuring the levels of the medications in the body and ensuring that they do not have adverse effects.

    • Siponimod
    • Ofatumumab
    • Fingolimod
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    • Tolebrutinib/SAR442168
  • Study on the effects of the new medication on patient with motor neuropathy

    This medical trial is designed to study a drug called ARGX-117 and how safe it is for adults who suffer from Multifocal Motor Neuropathy, a nerve condition that affects the muscles. This is a phase 2 trial. It means the researchers have done initial tests already and now they need to run more detailed tests. The researchers are testing two different amounts (doses) of the drug. Some participants will get the real drug and some will get the placebo. To keep it fair and unbiased, neither the patients nor the doctors will know who gets what. Additionally, the researchers are also checking how the drug moves in and out of the body and how it impacts the disease. For everyone taking part it will be recorded the strength of their handgrip over three days using a device called martin vigorimeter. And also they take an average of this grip strength to see any changes after using the drug.

    • ARGX-117
  • Study testing new chemotherapy combination for aggressive B-Cell Lymphoma treatment

    This study is for people over 60 who have never been treated for an aggressive type of blood cancer, called B-cell lymphoma, and who can’t receive the regular treatment, called R-CHOP. Instead of traditional chemotherapy, researchers will use the light treatment concept R-Pola-Glo that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo). The trial will look at factors like how long it takes for the disease to come back or get worse, the response rates after 2, 6, and 12 treatment cycles, and the percentage of people who experience side effects. It will also consider the effect on life quality, using two surveys designed by cancer research organizations.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Comparing new drug-Cytarabine Danuorubicin with standard chemotheraphy in adults with Acute Myeloid Leukemia

    This study is comparing two types of strong medicine, or ‘chemotherapy’, used to treat a disease called Acute Myeloid Leukemia (AML). This disease can sometimes be harder to treat in some patients due to their genetics. In this study, some people will get the usual strong medicine, and some people will get a new type of strong medicine called CPX-351 (Cytarabine and Danuorubicin). The researchers will also look at who might get fully or almost fully better from the disease.This trial is investigating how a new kind of very strong drug, CPX-351, might work compared to the usual strong drug treatment for a blood cancer called Acute Myeloid Leukemia (AML). These drugs are used when someone has recently found out they have AML, and their body has certain genetic markers making it harder for usual treatments to work. This trial is also looking at different degrees of recovery. The treatments may work differently based on people’s genes.

    • Cytarabine and Danuorubicin/CPX-351
    • Cytarabine
    • Daunorubicin
  • Evaluating the impact of upadacitinib on Hidradenitis Suppurativa

    The aim of this study is to evaluate the effects of a drug called upadacitinib on people suffering from a skin condition called Hidradenitis Suppurativa (HS). HS causes painful sores, mainly in areas such as the armpits, groin, and anal and genital areas. The drug has already been approved to treat other conditions, such as ulcerative colitis and rheumatoid arthritis, but now doctors want to see if it can help HS patients who don’t respond to current treatments. The study was divided into three parts. First, participants will be randomly assigned to two different groups, one group will take upadacitinib and the other will take a placebo (a substance with no active effect). Neither participants nor doctors will know what treatment a person is receiving. The study lasts a year and a half, and patients take pills every day. Depending on the results obtained, they may proceed to further stages of the study. Participants’ health will be closely monitored through regular check-ups, surveys, and monitoring for any side effects.

    • Upadacitinib
  • Study on new immunotherapy and its effect on genital herpes

    This study is about a new therapy being tried out on people aged 18-60 who either don’t have herpes, or who suffer from genital herpes. It seeks to check how people’s bodies are reacting to a new treatment meant to fight herpes simplex virus (HSV), whether it’s safe, and if it causes the body to develop an immune defense against the virus. Firstly, they will check how the new vaccine works on people aged 18-40 who don’t have herpes. Then they will do the same tests on men and women aged 18-60 who are suffering from genital herpes. Some of the side effects from the treatment might involve pain, redness, swelling, fever, fatigue, headache, and joint or muscle pain. They will measure fever using a thermometer placed in the mouth. In the study, they will record any unexpected side effects or ones that occur seven days after each treatment. These could be symptoms or illnesses that require a visit to a doctor or the hospital.

    • Non-adjuvanted HSV
    • HSVTI_F2
    • HSVTI_F1

See more clinical trials in other cities in Germany: